OBJECTIVE: Osteopontin (OPN) is associated with human abdominal aortic aneurysms (AAA) and in vitro studies suggest that this cytokine is downregulated by peroxisome proliferator-activated receptor (PPAR) ligation. We examined the effect of two PPAR ligands within a mouse model of aortic aneurysm. METHODS: At 11 weeks of age apolipoprotein E deficient (ApoE(-/-)) mice were given pioglitazone (n=27), fenofibrate (n=27) or vehicle (n=27) in their drinking water. From 13 weeks of age mice received angiotensin II (1 microg/kg/min) infusion via subcutaneous pumps until death or 17 weeks when the aortas were harvested and maximum aortic diameters were recorded. Suprarenal aortic segments were assessed for OPN concentration and macrophage accumulation. Saline infused mice served as negative controls (n=22). RESULTS: Angiotensin II induced marked dilatation in the suprarenal aorta (>2-fold increase compared to controls) associated with upregulation of the cytokines OPN and macrophage infiltration. Suprarenal aortic expansion was significantly reduced by administration of pioglitazone (mean diameter 1.61+/-0.11 mm, p=0.011) and fenofibrate (mean diameter 1.51+/-0.13 mm, p=0.001) compared to the vehicle control group (mean diameter 2.10+/-0.14 mm). Immunostaining for macrophages was reduced in mice treated with pioglitazone (median staining area 6.2%, interquartile range 4.1-7.2, p<0.001) and fenofibrate (median staining area 4.0%, interquartile range 2.2-6.1, p<0.001) compared to mice receiving vehicle control (median staining area 13.2%, interquartile range 8.4-20.0). CONCLUSION: These findings suggest the potential value of peroxisome proliferator-activated receptor ligation as a therapy for human AAAs. Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
OBJECTIVE:Osteopontin (OPN) is associated with humanabdominal aortic aneurysms (AAA) and in vitro studies suggest that this cytokine is downregulated by peroxisome proliferator-activated receptor (PPAR) ligation. We examined the effect of two PPAR ligands within a mouse model of aortic aneurysm. METHODS: At 11 weeks of age apolipoprotein E deficient (ApoE(-/-)) mice were given pioglitazone (n=27), fenofibrate (n=27) or vehicle (n=27) in their drinking water. From 13 weeks of age mice received angiotensin II (1 microg/kg/min) infusion via subcutaneous pumps until death or 17 weeks when the aortas were harvested and maximum aortic diameters were recorded. Suprarenal aortic segments were assessed for OPN concentration and macrophage accumulation. Saline infused mice served as negative controls (n=22). RESULTS: Angiotensin II induced marked dilatation in the suprarenal aorta (>2-fold increase compared to controls) associated with upregulation of the cytokines OPN and macrophage infiltration. Suprarenal aortic expansion was significantly reduced by administration of pioglitazone (mean diameter 1.61+/-0.11 mm, p=0.011) and fenofibrate (mean diameter 1.51+/-0.13 mm, p=0.001) compared to the vehicle control group (mean diameter 2.10+/-0.14 mm). Immunostaining for macrophages was reduced in mice treated with pioglitazone (median staining area 6.2%, interquartile range 4.1-7.2, p<0.001) and fenofibrate (median staining area 4.0%, interquartile range 2.2-6.1, p<0.001) compared to mice receiving vehicle control (median staining area 13.2%, interquartile range 8.4-20.0). CONCLUSION: These findings suggest the potential value of peroxisome proliferator-activated receptor ligation as a therapy for human AAAs. Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
Authors: Frank A Lederle; Samuel E Wilson; Gary R Johnson; Donovan B Reinke; Fred N Littooy; Charles W Acher; David J Ballard; Louis M Messina; Ian L Gordon; Edmund P Chute; William C Krupski; Steven J Busuttil; Gary W Barone; Steven Sparks; Linda M Graham; Joseph H Rapp; Michel S Makaroun; Gregory L Moneta; Robert A Cambria; Raymond G Makhoul; Darwin Eton; Howard J Ansel; Julie A Freischlag; Dennis Bandyk Journal: N Engl J Med Date: 2002-05-09 Impact factor: 91.245
Authors: Eric F Steinmetz; Celine Buckley; Murray L Shames; Terri L Ennis; Sarah J Vanvickle-Chavez; Dongli Mao; Lee A Goeddel; Cherady J Hawkins; Robert W Thompson Journal: Ann Surg Date: 2005-01 Impact factor: 12.969
Authors: Dennis Bruemmer; Alan R Collins; Grace Noh; Wei Wang; Mary Territo; Sarah Arias-Magallona; Michael C Fishbein; Florian Blaschke; Ulrich Kintscher; Kristof Graf; Ronald E Law; Willa A Hsueh Journal: J Clin Invest Date: 2003-11 Impact factor: 14.808
Authors: Gorav Ailawadi; Jonathan L Eliason; Karen J Roelofs; Indranil Sinha; Kevin K Hannawa; Eric P Kaldjian; Guanyi Lu; Peter K Henke; James C Stanley; Stephen J Weiss; Robert W Thompson; Gilbert R Upchurch Journal: Arterioscler Thromb Vasc Biol Date: 2004-08-26 Impact factor: 8.311
Authors: N van Royen; I Hoefer; M Böttinger; J Hua; S Grundmann; M Voskuil; C Bode; W Schaper; I Buschmann; J J Piek Journal: Circ Res Date: 2003-02-07 Impact factor: 17.367
Authors: Baby Martin-McNulty; Doris M Tham; Valdeci da Cunha; Jerrick J Ho; Dennis W Wilson; John C Rutledge; Gary G Deng; Ronald Vergona; Mark E Sullivan; Yi-Xin Wang Journal: Arterioscler Thromb Vasc Biol Date: 2003-07-10 Impact factor: 8.311
Authors: Venkateswaran Subramanian; Jonathan Golledge; Talha Ijaz; Dennis Bruemmer; Alan Daugherty Journal: Circ Res Date: 2010-08-26 Impact factor: 17.367
Authors: David M Hasan; Robert M Starke; He Gu; Katina Wilson; Yi Chu; Nohra Chalouhi; Donald D Heistad; Frank M Faraci; Curt D Sigmund Journal: Hypertension Date: 2015-04-27 Impact factor: 10.190
Authors: Dylan R Morris; Margaret A Cunningham; Anna A Ahimastos; Bronwyn A Kingwell; Elise Pappas; Michael Bourke; Christopher M Reid; Theo Stijnen; Ronald L Dalman; Oliver O Aalami; Jan H Lindeman; Paul E Norman; Philip J Walker; Robert Fitridge; Bernie Bourke; Anthony E Dear; Jenna Pinchbeck; Rene Jaeggi; Jonathan Golledge Journal: Trials Date: 2015-06-17 Impact factor: 2.279
Authors: Sai Wang Seto; Smriti M Krishna; Hongyou Yu; David Liu; Surabhi Khosla; Jonathan Golledge Journal: PLoS One Date: 2013-03-04 Impact factor: 3.240